Revolution Medicines, Inc. (RVMD) Tops Q3 EPS by 200c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of $0.99, $2.00 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $0 versus the consensus estimate of $750 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Deutsche Bank Upgrades Wickes Group plc (WIX:LN) to Hold